What is Aspect Biosystems?
Aspect Biosystems is a biotechnology firm operating at the intersection of advanced manufacturing and life sciences. Its core technology, the Lab-on-a-Printer platform, enables the creation of complex, human-relevant tissues that are essential for modern disease research and the development of novel therapeutics. By bridging the gap between fundamental biology and commercial application, Aspect Biosystems provides pharmaceutical and biotechnology companies with the tools required to accelerate the discovery of life-changing therapies. The company's market position is defined by its ability to deliver high-fidelity tissue models that improve the predictive power of drug development pipelines, thereby reducing the time and cost associated with bringing new treatments to market.
How much funding has Aspect Biosystems raised?
Aspect Biosystems has raised a total of $215M across 4 funding rounds:
Other Financing Round
$1M
Series A
$20M
Series B
$115M
Unspecified
$79M
Other Financing Round (2018): $1M with participation from Genome British Columbia
Series A (2020): $20M led by Pallasite Ventures, Radical Ventures, Rhino Ventures, and Pangaea Ventures
Series B (2025): $115M supported by Dimension Data, Pallasite Ventures, Novo Nordisk, Radical Ventures, Rhino Ventures, InBC Investment, JDRF T1D Fund, and Pangaea Ventures
Unspecified (2026): $79M featuring Government of Canada
Key Investors in Aspect Biosystems
Novo Nordisk
A global pharmaceutical leader specializing in biological medicines for diabetes, obesity, and rare blood disorders, focusing on innovative drug delivery systems.
Radical Ventures
A venture capital firm that invests in bold entrepreneurs applying artificial intelligence and deep technologies to solve complex future challenges.
Pangaea Ventures
A specialized venture capital firm focusing on hard tech and materials science to drive industrial transformation and sustainability in biotechnology.
What's next for Aspect Biosystems?
With this latest capital, Aspect Biosystems is poised to transition into a new phase of commercial expansion and technological refinement. The strategic focus will likely center on deepening its partnerships with global pharmaceutical leaders to integrate its bioprinted tissues into standard drug screening workflows. Furthermore, the company is expected to leverage its increased financial runway to scale its internal R&D capabilities, potentially exploring new therapeutic areas within regenerative medicine. As the firm continues to mature, the emphasis will remain on maintaining its leadership in the 3D bioprinting sector while demonstrating the long-term clinical and commercial utility of its engineered tissue solutions.
See full Aspect Biosystems company page
